Mixed Data Cloud Future Of Sunovion's ADHD Drug
Executive Summary
Sunovion's ADHD drug, dasotraline, has missed its primary endpoint in a Phase III study in adult patients but has reported mixed results in children, prompting the company to continue pursuing its 2017 plans for an FDA filing in both age groups. But data for the non-stimulant ADHD therapy suggest it will be tricky to overthrow market stalwarts.
You may also be interested in...
Keeping Track: Busy August Ends With Approval For Doravirine, CRLs For Dasotraline And Waylivra
The latest drug development news and highlights from our US FDA Performance Tracker.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.